By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Poxel SAS 

200 avenue Jean Jaures

Lyon    69007  France
Phone: 33-4-37-372010 Fax: 33-4-37-708815



Company News
Poxel SAS Closes a €26.5 Million Capital Increase 7/18/2016 10:33:27 AM
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016 9:10:39 AM
Poxel SAS Announces Positive Results From the First Stage Of The Ongoing PXL770 Phase 1 Trial 6/20/2016 11:56:13 AM
Poxel Presents New Data On Imeglimin’s Dual Mechanism Of Action At The American Diabetes Association’s 76th Scientific Sessions 6/13/2016 10:49:13 AM
Poxel Has Been Granted U.S. Composition Of Matter Patent For Direct AMPK Activator PXL770 For The Potential Treatment Of Type 2 Diabetes And Related Disorders 3/29/2016 11:12:31 AM
Poxel SAS Appoints Jonae R. Barnes As Senior Vice President Investor Relations And Public Relations, Based In Boston 3/14/2016 9:06:57 AM
Poxel SAS Appoints Janice Bourque And Pierre Legault To Its Board Of Directors 2/1/2016 10:25:41 AM
Poxel Release: Imeglimin’s Innovative Mitochondria-Targeted Mechanism Of Action Recognized By The Scientific Committee Of The World Mitochondria Society 11/2/2015 10:24:55 AM
Poxel SAS Raises $17 Million to Progress Imeglimin Development to Treat Type 2 Diabetes 12/18/2012 6:36:52 AM
New Clinical Results for an Anti-Diabetic Compound in Development at Poxel SAS 10/26/2011 8:58:53 AM